Research Article
[Retracted] Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation
Table 3
Distribution of bleeding events according to the bleeding risk scores categories n (%).
| | | | ABC-AF bleeding score | HAS-BLED score | | N | GDF-15 (pg/mL) | Low/medium risk | High risk | Low/medium risk | High risk |
| | Non-bleeding events | 211 (100) | 3,718.67 ± 3,646.01 | 47 (22.27) | 164 (77.73) | 87 (41.23) | 124 (58.77) | | All bleeding events | 131 (100) | 6,047.87 ± 5,346.50 | 12 (9.16) | 119 (90.84) | 26 (19.85) | 105 (80.15) | | Major bleeding | 6 (100) | 5,256.17 ± 3,857.65 | 0 (0) | 6 (100) | 0 (0) | 6 (100) | | CRNM GIB | 57 (100) | 7,396.96 ± 5,747.45 | 2 (3.51) | 55 (96.49) | 3 (11.54) | 54 (94.74) | | OB positive | 36 (100) | 6,159.11 ± 5,790.49 | 4 (11.11) | 32 (88.89) | 6 (23.08) | 30 (83.33) | | Other minor bleeding | 32 (100) | 3,668.09 ± 3,258.10 | 6 (18.75) | 26 (81.25) | 17 (65.38) | 15 (46.88) |
|
|
Note: NVAF, nonvalvular atrial fibrillation; MB, major bleeding; CRNM GIB, clinically relevant nonmajor gastrointestinal bleeding; OB positive, fecal occult blood positive; NAT, no antithrombotic treatment; AP, antiplatelet; VKA, vitamin K antagonists; and NOACs, non-vitamin K antagonist.
|
